Meeting
2023 ASCO Annual Meeting
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
Authors
John Heymach
Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX
John Heymach , Frans Opdam , Minal A. Barve , Hai-Yan Tu , Yi-Long Wu , David Berz , Neil Gibson , Behbood Sadrolhefazi , Josep Serra , Kiyotaka Yoh , Noboru Yamamoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04886804
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8545)
DOI
10.1200/JCO.2023.41.16_suppl.8545
Abstract #
8545
Poster Bd #
172
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.
First Author: Tejas Patil
Poster
2018 ASCO Annual Meeting
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.
First Author: Zandong Yang
Poster
2013 ASCO Annual Meeting
Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations.
First Author: Leena Gandhi
Poster
2023 ASCO Annual Meeting
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
First Author: Jordi Rodon Ahnert